8-(benzyloxy)-[1,2,4]triazolo[4,3-a]pyridine | 1065608-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 8-(benzyloxy)-[1,2,4]triazolo[4,3-a]pyridine
• 英文别名: 8-Phenylmethoxy-1,2,4-triazolo[4,3-a]pyridine；8-Phenylmethoxy-1,3,4-triazolo[1,5-a]pyridine；8-phenylmethoxy-[1,2,4]triazolo[4,3-a]pyridine
• CAS: 1065608-70-9
• 化学式: C₁₃H₁₁N₃O
• 分子量: 225.25
• InChiKey: RRNNBDOHOLRFLB-UHFFFAOYSA-N

物化性质

• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-(benzyloxy)-[1,2,4]triazolo[4,3-a]pyridine 在 palladium on activated charcoal 、 氢气 、 戴斯-马丁氧化剂 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 生成 4,5,6,7-四氢-2,1,3-苯并噁二唑-4-酮
  参考文献：
  名称：

  Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors

  摘要：

  A class of imidazoisoindole (III) heme-binding indoleamine-2,3-dioxygenase (IDO1) inhibitors were optimized via structure-based drug design into a series of tryptophan-2,3-dioxygenase (TDO)-selective inhibitors. Kynurenine pathway modulation was demonstrated in vivo, which enabled evaluation of TDO as a potential cancer immunotherapy target. As means of mitigating the risk of drug-drug interactions arising from cytochrome P450 inhibition, a novel property-based drug design parameter, herein referred to as the CYP Index, was implemented for the design of inhibitors with appreciable selectivity for TDO over CYP3A4. We anticipate the CYP Index will be a valuable design parameter for optimizing CYP inhibition of any small molecule inhibitor containing a Lewis basic motif capable of binding heme.

  DOI：

  10.1021/acsmedchemlett.0c00004
• 作为产物：
  描述：

  3-benzyloxy 2-chloropyridine 在 potassium carbonate 、 肼 作用下， 以 叔丁醇 为溶剂， 反应 123.0h， 生成 8-(benzyloxy)-[1,2,4]triazolo[4,3-a]pyridine
  参考文献：
  名称：

  [EN] TDO2 INHIBITORS
  [FR] INHIBITEURS DE TDO2

  摘要：

  目前提供了细胞表达的TDO2的抑制剂及其药物组合物，用于调节色氨酸2,3双氧酶的活性；治疗免疫抑制；治疗受益于色氨酸降解抑制的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；以及治疗与癌症相关的肿瘤特异性免疫抑制。

  公开号：

  WO2017107979A1

文献信息

• [EN] TDO2 INHIBITORS<br/>[FR] INHIBITEURS DE TDO2
  申请人：GENENTECH INC

  公开号：WO2017107979A1

  公开（公告）日：2017-06-29

  Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

  目前提供了细胞表达的TDO2的抑制剂及其药物组合物，用于调节色氨酸2,3双氧酶的活性；治疗免疫抑制；治疗受益于色氨酸降解抑制的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；以及治疗与癌症相关的肿瘤特异性免疫抑制。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas Daniel

  公开号：US20100105659A1

  公开（公告）日：2010-04-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病中非常有用，例如糖尿病。同时提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• 2-aminopyridine analogs as glucokinase activators
  申请人：Aicher Thomas Daniel

  公开号：US08362037B2

  公开（公告）日：2013-01-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病（如糖尿病）方面非常有用。同时还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶来治疗的疾病和疾病的方法。
• TDO2 Inhibitors
  申请人：Genentech, Inc.

  公开号：US10800780B2

  公开（公告）日：2020-10-13

  Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

  目前提供的是细胞表达的 TDO2 的抑制剂及其药物组合物，可用于调节色氨酸 2，3 二氧 化酶的活性；治疗免疫抑制；治疗从抑制色氨酸降解中获益的病症；提高包括施用抗癌剂在内的抗癌治疗的效果；以及治疗与癌症相关的肿瘤特异性免疫抑制。
• WO2008/118718
  申请人：——

  公开号：——

  公开（公告）日：——